Moxetumomab (CAS: 1622075-65-3)
Moxetumomab is a recombinant immunotoxin that targets CD22, a protein expressed on B cells. It is primarily used in the treatment of hairy cell leukemia (HCL), a rare blood cancer.
Key Features:
- Target: Binds specifically to CD22 on B cells.
- Mechanism: Delivers a cytotoxic agent directly to CD22-expressing cells, leading to their destruction.
- Therapeutic Use: Approved for treating adults with relapsed or refractory HCL, particularly those who have received at least two prior systemic therapies, including purine nucleoside analogs.
Applications:
- Cancer Treatment: Moxetumomab targets and eliminates malignant B cells in HCL.
- Research: Used as a model for developing other immunotoxins targeting different cancer antigens.
Handling and Storage:
- Formulation: Available as a lyophilized powder for reconstitution.
- Storage: Store at -20°C, protected from light.
- Precautions: Use personal protective equipment and ensure proper ventilation during handling.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
